The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients
- 1 December 1989
- journal article
- conference paper
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 1 (4) , 297-302
- https://doi.org/10.1007/bf02263483
Abstract
The coenzyme nicotinamide adenine dinucleotide (NADH) has been used in an open label trial as novel medication in 34 patients with Parkinson's disease, using an intravenous administration technique. In all patients a beneficial clinical effect was observed. 21 patients (61.7%) showed a very good (better than 30%) improvement of disability, 13 patients (38.3%) a moderate (up to 30%) improvement. Concomitant with the improvement of the disability the urine level of homovanillic acid (HVA) increased significantly in all patients (in some patients by more than a 100%). The daily “on phases” of the patients could be increased from 2 up to 9 hours in the individual patients by NADH administration.Keywords
This publication has 5 references indexed in Scilit:
- IMPROVEMENT OF DISABILITY AND AKINESIA OF PATIENTS WITH PARKINSONS-DISEASE BY INTRAVENOUS IRON SUBSTITUTION1987
- Iron, a new aid in the treatment of Parkinson patientsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- BIOSYNTHESIS AND METABOLISM OF TETRAHYDROBIOPTERIN AND MOLYBDOPTERINAnnual Review of Biochemistry, 1985
- Die Parkinson-KrankheitPublished by Springer Nature ,1985
- Biopterin in human brain and urine from controls and parkinsonian patients: Application of a new radioimmunoassayClinica Chimica Acta; International Journal of Clinical Chemistry, 1981